Jane Street’s Candel Therapeutics CADL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$742K Buy
151,500
+19,100
+14% +$104K ﹤0.01% 7142
2025
Q4
$748K Buy
132,400
+22,000
+20% +$118K ﹤0.01% 6790
2025
Q3
$563K Sell
110,400
-35,900
-25% -$207K ﹤0.01% 7602
2025
Q2
$740K Buy
146,300
+90,200
+161% +$464K ﹤0.01% 6187
2025
Q1
$317K Buy
56,100
+25,900
+86% +$212K ﹤0.01% 7710
2024
Q4
$262K Buy
+30,200
New +$178K ﹤0.01% 7955

Other funds holding CADL

Jane Street's CADL Position: Q1 2026 in Review

Jane Street sold out of Candel Therapeutics (CADL) in Q1 2026, closing a stake of 10,799 shares — an estimated $58.8K sold.

Jane Street first reported a position in CADL in Q4 2022 and held it in 5 quarters. The position peaked at $227K in Q3 2024. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Jane Street reported no remaining Candel Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 10,799 Candel Therapeutics shares in Q1 2026, an estimated $58.8K.
  • Jane Street first reported a position in Candel Therapeutics in Q4 2022 and held it in 5 quarters.
  • Jane Street's Candel Therapeutics position peaked at $227K in Q3 2024.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.